PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
AboutPricing
Drug ReportsErythromycin lactobionate
Erythromycin lactobionate
Benzamycin, E.e.s, Ery-tab, Eryc, Erygel, Eryped, Erythrerm, Erythrocin, Erythromycin, Eryzole, Ilosone, Ilotycin, Pediazole (erythromycin lactobionate) is a small molecule pharmaceutical. Erythromycin lactobionate was first approved as Ilotycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, campylobacter infections, and chancroid amongst others in the USA.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
digestive system diseasesD004066
respiratory tract diseasesD012140
eye diseasesD005128
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
Trade Name
FDA
EMA
Erythrocin, Erythromycin lactobionate (discontinued: Erythrocin, Erythromycin, Erythromycin lactobionate)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Erythromycin lactobionate
Tradename
Company
Number
Date
Products
ERYTHROCINHospiraN-050609 RX1986-09-24
1 products, RLD, RS
Show 2 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
erythrocin lactobionateNew Drug Application2025-10-30
erythrocin stearateANDA2015-07-31
erythromycin lactobionateANDA2024-11-20
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
acne vulgarisEFO_0003894D000152L70
bacterial infections—D001424A49
gonorrheaDOID_7551D006069A54
campylobacter infectionsEFO_0007190D002169—
whooping coughEFO_0000650D014917A37
chlamydia infectionsEFO_0007205D002690A74.9
streptococcal infectionsEFO_1001476D013290—
legionnaires' diseaseEFO_0007343D007877A48.1
urethritisEFO_0003878D014526N34
bacterial eye infections—D015818—
Show 7 more
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF02: Erythromycin
— D10AF52: Erythromycin, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA01: Erythromycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA17: Erythromycin
HCPCS
Code
Description
J1364
Injection, erythromycin lactobionate, per 500 mg
Clinical
Clinical Trials
1023 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
InfectionsD007239EFO_0000544—1425376358191
Communicable diseasesD003141——61921233196
Covid-19D000086382—U07.16253141169
Healthy volunteers/patients———51217767
Helicobacter infectionsD016481EFO_1000961——517231356
PneumoniaD011014EFO_0003106J181718141653
Mycobacterium avium-intracellulare infectionD015270EFO_0007386—18951032
Mycobacterium infectionsD009164—A31.9181021029
Lung diseasesD008171EFO_0003818J98.416109328
GastritisD005756EFO_0000217K29.722715227
Show 163 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B20778—1537
Multiple myelomaD009101—C90.02184——22
Plasma cell neoplasmsD054219——1134——17
Falciparum malariaD016778EFO_0007444B501128——15
LymphomaD008223—C85.9272—313
Coronavirus infectionsD018352EFO_0007224B34.2165—112
Respiratory insufficiencyD012131—J96.9—45—512
PeriodontitisD010518EFO_0000649K05.3—42—711
Sars-cov-2D000086402———64——9
InflammationD007249MP_0001845—113—38
Show 84 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
NeoplasmsD009369—C8044——19
B-cell lymphoma marginal zoneD018442—C88.4—4——37
SarcoidosisD012507EFO_0000690D80-D8923———4
Whooping coughD014917EFO_0000650A37—1——34
Chronic periodontitisD055113EFO_0006343K05.3—2——24
B-cell chronic lymphocytic leukemiaD015451—C91.113———4
HypercapniaD006935———1——34
Acute lung injuryD055371EFO_0004610—12——13
Pulmonary sarcoidosisD017565DOID_13406D86.012———3
Diabetes mellitusD003920EFO_0000400E08-E13—1——23
Show 90 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Drug interactionsD004347——7————7
Bacterial eye infectionsD015818——5————5
Long qt syndromeD008133HP_0001657I45.811———23
Depressive disorderD003866EFO_1002014F32.A1———23
Kidney diseasesD007674EFO_0003086N081———12
Prostatic neoplasmsD011471—C611———12
Major depressive disorderD003865EFO_0003761F221———12
Nephrotic syndromeD009404EFO_0004255N041———12
Amyotrophic lateral sclerosisD000690EFO_0000253G12.212————2
Type 2 diabetes mellitusD003924EFO_0001360E111———12
Show 32 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DepressionD003863—F33.9————55
Obstructive sleep apneaD020181EFO_0003918G47.33————44
Heart failureD006333EFO_0003144I50————33
CryptosporidiosisD003457—A07.2————33
DermatitisD003872—L30.9————33
ApneaD001049—R06.81————33
Sleep apnea syndromesD012891EFO_0003877G47.3————33
HyperaldosteronismD006929—E26————22
Attention deficit disorder with hyperactivityD001289EFO_0003888F90————22
Drug-related side effects and adverse reactionsD064420—T88.7————22
Show 149 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameErythromycin lactobionate
INNerythromycin
Description
Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is an erythromycin and a cyclic ketone. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin A(1+).
Classification
Small molecule
Drug classantibiotics (Streptomyces strain)
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O.O=C(O)[C@H](O)[C@@H](O)[C@H](O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O)[C@H](O)CO
Identifiers
PDB—
CAS-ID114-07-8
RxCUI4053
ChEMBL IDCHEMBL1200506
ChEBI ID—
PubChem CID12560
DrugBankDB00199
UNII ID63937KV33D (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
Pfizer – Protalix BioTherapeutics
Plot placeholder
Mock data
Subscribe for the real data
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Estimated US medical usage
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 435 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
506 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use